BCG-trained bone marrow-derived macrophages (BMDMs) inhibit tumor growth via IFN-γ release and reduce pro-tumor inflammatory responses by regulating chemokines (e.g., decreasing MCP-1), representing a novel function of TI 145. Here, IFNG is linked to neoplasm.